
This article analyzes gaps in US biosimilar development, quantifies market opportunities, and proposes policy and economic solutions to improve cost savings and patient access.
The American Journal of Managed Care
over 23 years ago
Restoring Trust to Managed Care, Part 2: A Focus on Physiciansover 23 years ago
Review of the Newer Antiepileptic Drugs